On the stock market since 2014, it operates in the world of health and science. It has 131 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 77% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $269.0M in the vault; even if every debt were paid off, $259.1M would remain.
The average analyst price target is $72.00 — 86% above today’s price.
A loss of $90.4M against $0 in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 8/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 33/100.
On our five-subject report card, NGNE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NGNE is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (33/100) says the stock isn’t cheap.